Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
SAN JOSE — Zebra Technologies and bioMerieux reported to the state Employment Development Department their separate decisions to cut jobs in moves that will eliminate a combined 196 positions in San ...
Gov. Maura Healey is expected to be in Norton Wednesday morning to announce some good news: a $250 million expansion of a manufacturing plant run by Alnylam Pharmaceuticals, a publicly traded biotech ...
As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look to opportunities to be had within other sectors. Undoubtedly, the ...
The 2025 Big 12 season has come to an end, and the final results look far different than preseason outlooks. Texas Tech blew away expectations to earn its first outright conference title since 1955, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This Cambridge biotech is ...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on ...
Dec 10 (Reuters) - French biotech company Abivax's (ABVX.PA), opens new tab shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly (LLY.N), opens new tab could make an ...
Abivax SA’s (NASDAQ: ABVX) stock is trading higher on Wednesday. The stock reacted to market rumours that U.S. pharma giant Eli Lilly and Co (NYSE: LLY) could make an offer. • Abivax stock is charging ...
In the fast-paced world of biotechnology, success hinges on more than groundbreaking science—it requires the right connections, strategic partnerships, and access to capital. Biotech Showcase delivers ...
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. WASHINGTON — Congress is poised ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Beverly biotech is working ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback